# Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease)

> **NCT05532813** · PHASE3 · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 142 (estimated)

## Conditions studied

- Steinert's Disease
- Myotonic Dystrophy 1
- Metformin

## Interventions

- **DRUG:** Treatment taken

## Key facts

- **NCT ID:** NCT05532813
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-29
- **Primary completion:** 2026-11
- **Final completion:** 2026-12
- **Target enrollment:** 142 (ESTIMATED)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05532813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05532813, "Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease)". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05532813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*